Kyverna Therapeutics, Inc.

Contributing Author

Recent Articles by Kyverna Therapeutics, Inc.

Sep-15	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 KYTX GlobeNewswire
Aug-28	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event KYTX GlobeNewswire
Aug-25	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September KYTX GlobeNewswire
Aug-12	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results KYTX GlobeNewswire